Recent Updates
Recently added Catalysts

Valacyclovir

Phase 1

Healthy | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Jun 14, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment75
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01136525Bioavailability Study of Valacyclovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fasting ConditionsPHASE1 COMPLETED 41Feb 1, 2007May 1, 2007Jun 14, 20101 India
NCT01136538Bioavailability Study of Valacycovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fed ConditionPHASE1 COMPLETED 34Feb 1, 2007May 1, 2007Jun 14, 20101 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence based on Cmax and AUC parameters
4 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Valacyclovir HydrochlorideEXPERIMENTALValacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Valtrex (R)ACTIVE_COMPARATORValtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
Interventions
NameTypeDescription
Valacyclovir HydrochlorideDRUGValacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: The subjects were selected for study participation, based on the following criteria: 1. Human subjects aged between 18 and 45 years (including both). 2. Subjects' weight within the normal range according to normal values for the Body Mass Index (18.5 to 24.9 kg/m2) with minimum...

Countries:India
Unlock Eligibility Criteria